Journal of Neurology

, Volume 260, Issue 12, pp 3030–3038 | Cite as

Intravenous amantadine on freezing of gait in Parkinson’s disease: a randomized controlled trial

  • Jee Young Lee
  • Sohee Oh
  • Jong Min Kim
  • Ji Sun Kim
  • Eungseok Oh
  • Hee-Tae Kim
  • Beom S. Jeon
  • Jin Whan Cho
Original Communication

Abstract

To compare the effects of intravenous amantadine and placebo therapy on freezing of gait in patients with Parkinson’s disease, this randomized, double-blind, placebo-controlled, multicenter trial compared the efficacy of 5 days intravenous amantadine and placebo treatments on freezing of gait in 42 subjects randomly allocated 2:1 to amantadine or placebo groups. Changes in freezing of gait questionnaire (FOG-Q) scores and in unified Parkinson’s disease rating scale (UPDRS) scores, from baseline to immediately (V1) and 1 month (V2) after treatments, were assessed. Among the 42 patients (amantadine n = 29, placebo n = 13, a mean age 65.5 ± 9.4 years and a mean FOG-Q score 17.4 ± 3.2), 40 subjects completed treatment. There was no significant group difference on the primary outcome measure as total FOG-Q score changes at V1. However a significant beneficial effect of amantadine on freezing was seen at V2 in the UPDRS Part II freezing and FOG-Q item 3 scores, and there was significant improvement in the UPDRS Part IV total score and in the UPDRS Part II getting out of bed score in the amantadine group at both V1 and V2. There was no serious adverse event reported during the study. The intravenous amantadine therapy did not show a significant improvement on overall FOG-Q scores in patients with moderate-to-severe freezing; however, it might be beneficial by attenuating freezing severity and improving patients’ mobility. To prove this finding further studies with larger sample sizes are warranted in the future.

Keywords

Freezing of gait Parkinson’s disease Intravenous amantadine Randomized-controlled trial 

Supplementary material

415_2013_7108_MOESM1_ESM.docx (19 kb)
Supplementary material 1 (DOCX 18 kb)
415_2013_7108_MOESM2_ESM.docx (20 kb)
Supplementary material 2 (DOCX 20 kb)

References

  1. 1.
    Schwab RS, England AC Jr, Poskanzer DC, Young RR (1969) Amantadine in the treatment of Parkinson’s disease. JAMA 208:1168–1170PubMedCrossRefGoogle Scholar
  2. 2.
    Parkes JD, Calver DM, Zilkha KJ, Knill-Jones RP (1970) Controlled trial of amantadine hydrochloride in Parkinson’s disease. Lancet 1:259–262PubMedCrossRefGoogle Scholar
  3. 3.
    Lupp A, Lucking CH, Koch R, Jackisch R, Feuerstein TJ (1992) Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 263:717–724PubMedGoogle Scholar
  4. 4.
    Blanpied TA, Clarke RJ, Johnson JW (2005) Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 25:3312–3322PubMedCrossRefGoogle Scholar
  5. 5.
    Lange KW, Kornhuber J, Riederer P (1997) Dopamine/glutamate interactions in Parkinson’s disease. Neurosci Biobehav Rev 21:393–400PubMedCrossRefGoogle Scholar
  6. 6.
    Okuma Y (2006) Freezing of gait in Parkinson’s disease. J Neurol 253(supp7):VII27–VII32PubMedGoogle Scholar
  7. 7.
    Giladi N (2008) Medical treatment of freezing of gait. Mov Disord 23(supp 2):S482–S488PubMedCrossRefGoogle Scholar
  8. 8.
    Devos D, Defebvre L, Bordet R (2010) Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease. Fundam Clin Pharmacol 24:407–421PubMedCrossRefGoogle Scholar
  9. 9.
    Skuza G, Rogoz Z, Quack G, Danysz W (1994) Memantine, amantadine, and l-deprenyl potentiate the action of l-dopa in monoamine-depleted rats. J Neural Transm Gen Sect 98:57–67PubMedCrossRefGoogle Scholar
  10. 10.
    Giladi N, Treves TA, Simon ES et al (2001) Freezing of gait in patients with advanced Parkinson’s disease. J Neural Transm 108:53–61PubMedCrossRefGoogle Scholar
  11. 11.
    Kondo T (2006) Drug intervention for freeizng of gait resistant to dopaminergic therapy: a pilot study. Parkinsonism Relat Disord 12:S63–S66CrossRefGoogle Scholar
  12. 12.
    Kim YE, Yun JY, Jeon BS (2011) Effect of intravenous amantadine on dopaminergic-drug- resistant freezing of gait. Parkinsonism Relat Disord 17:491–492PubMedCrossRefGoogle Scholar
  13. 13.
    Kim YE, Yun JY, Yang HJ et al (2012) Intravenous amantadine for freezing of gait resistant to dopaminergic therapy: a randomized, double-blind, placebo-controlled, crossover clinical trial. PLoS One 7(11):e48890PubMedCrossRefGoogle Scholar
  14. 14.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCrossRefGoogle Scholar
  15. 15.
    Giladi N, Shabtai H, Simon ES, Biran S, Tal J, Korczyn AD (2000) Construction of freezing of gait questionnaire for patients with parkinsonism. Parionsonism Relat Disord 6:165–170CrossRefGoogle Scholar
  16. 16.
    Růzicka E, Streitová H, Jech R et al (2000) Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson’s disease. J Neural Transm 107:1297–1306PubMedCrossRefGoogle Scholar
  17. 17.
    Del Dotto P, Pavese N, Gambaccini G et al (2001) Intravenous amantadine improves levodopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 16:515–520PubMedCrossRefGoogle Scholar
  18. 18.
    Pinter MM, Birk M, Helscher J, Binder H (1999) Short-term effect of amantadine sulphate on motor performance and reaction time in patients with idopathic Parkinson’s disease. J Neural Transm 106:711–724PubMedCrossRefGoogle Scholar
  19. 19.
    Muller T, Kuhn W, Schulte T, Przuntek H (2003) Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson’s disease. Neurosci Lett 339:25–28PubMedCrossRefGoogle Scholar
  20. 20.
    Inzelberg R, Bonuccelli U, Schechtman E et al (2006) Association between amantadine and the onset of dementia in Parkinson’s disease. Mov Disord 21:1375–1379PubMedCrossRefGoogle Scholar
  21. 21.
    Amboni M, Cozzolino A, Longo K, Picillo M, Barone P (2008) Freezing of gait and executive functions in patients with Parkinson’s disease. Mov Disord 23:395–400PubMedCrossRefGoogle Scholar
  22. 22.
    Müller T, Kuhn W, Quack G, Przuntek H (1995) Intravenous application of amantadine and antiparkinsonian efficacy in Parkinsonian patients. J Neural Transm Suppl 46:407–413PubMedGoogle Scholar
  23. 23.
    Brenner M, Haass A, Jacobi P, Schimrigk K (1989) Amantadine sulphate in treating Parkinson’s disease: clinical effects, psychometric tests and serum concentrations. J Neurol 236:153–156PubMedCrossRefGoogle Scholar
  24. 24.
    Espay AJ, Fasano A, van Nuenen BF, Payne MM, Snijders AH, Bloem BR (2012) “On” state freezing of gait in Parkinson disease: a paradoxical levodopa-induced complication. Neurology 78:454–457PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Jee Young Lee
    • 1
  • Sohee Oh
    • 2
  • Jong Min Kim
    • 3
  • Ji Sun Kim
    • 4
  • Eungseok Oh
    • 3
  • Hee-Tae Kim
    • 5
  • Beom S. Jeon
    • 6
  • Jin Whan Cho
    • 4
  1. 1.Department of Neurology, Seoul National University-Seoul Metropolitan Government Boramae Medical CenterCollege of Medicine Seoul National UniversitySeoulRepublic of Korea
  2. 2.Department of Biostatistics, Seoul National University-Seoul Metropolitan Government Boramae Medical CenterCollege of Medicine Seoul National UniversitySeoulRepublic of Korea
  3. 3.Department of Neurology, Seoul National University Bundang HospitalCollege of Medicine Seoul National UniversitySeoulRepublic of Korea
  4. 4.Department of Neurology, Samsung Medical Center, College of Medicine Sungkyunkwan UniversitySungkyunkwan University School of MedicineSeoulRepublic of Korea
  5. 5.Department of Neurology, Hanyang University Medical centerCollege of Medicine Hanyang UniversitySeoulRepublic of Korea
  6. 6.Department of Neurology and Movement Disorders Center, Seoul National University HospitalCollege of Medicine Seoul National UniversitySeoulRepublic of Korea

Personalised recommendations